Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teikoku Pharma USA Inc.

Division of Teikoku Seiyaku Co. Ltd.
www.teikokuusa.com

Latest From Teikoku Pharma USA Inc.

Market Intel: Pain Is Biggest Market For Transdermal Drug Delivery But Not A Patch Over Neuro For Growth

The growing aging population and rising obesity rates are paving the way for patch-based drug delivery systems to treat such common age-related diseases as Alzheimer's and Parkinson's, hormonal deficiencies, heart disease, as well as for managing acute and chronic pain patients. According to a new report by Meddevicetracker, the global market for transdermal patch products will reach $8.1bn by 2021, a CAGR of 2.9% from 2016. In this feature, we'll take a closer look at the overall market and the key players in the individual segments in this overall market. We'll take a deep dive into the neurological disorders segment, which is expected to see the biggest growth in the overall segment. We'll also feature physician specialty surveys outlining the pros and cons of using patch-based systems.

Combination Products Market Intelligence

Pipeline Watch: Phase III Starts With Gilteritinib, Lumateperone, Pro 140

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

FTC Focus On Pay-For-Delay Deals Continues; Endo Agrees To 10-Year Abstention

In addition to settling with Endo, FTC refiles charges against Watson (now Teva), Allergan and Impax involving Lidoderm and Opana ER patent litigation settlements.

BioPharmaceutical Policy & Regulation

Deals Shaping the Medical Industry, October 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
      • Transdermal
  • Therapeutic Areas
  • Cancer
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Teikoku Seiyaku Co. Ltd.
  • Senior Management
  • Ichiro (Paul) Mori, Pres. & CEO
    Atsumu Matsushita, EVP, CFO
    Jutaro Shudo, PhD, SVP, CSO
    Francisco Bejar, VP, Licensing & Strategic Alliances
  • Contact Info
  • Teikoku Pharma USA Inc.
    Phone: (408) 501-1800
    1718 Ringwood Ave.
    San Jose, CA 95131
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register